Annual lecture as part of the ICICI Bank Chair in IIMA.by Prof. Chirantan Chatterjee.

1. ACKNOWLEDGMENTS
National Science Foundation, Sloan Foundation, Qualcomm University Initiatives, Pfizer’s International Policy Unit, IQVIA – Formerly
IMS Health India, SAST-VAS-Karnataka, All India Organization of Chemists and Druggists, IIMB Young Faculty Research Chair, ISB Bharti &
Max Institute Fellowship in Public Policy and Healthcare, IIMA R&P Grants, collaborators, friends and family.

2. TOWARDS A COMPASSIONATE COMPASS IN HEALTHCARE MARKETS
• "the purpose of human life is to
serve, and to show compassion and
the will to help others." – Albert
Schweitzer
• Dynamic Trade-offs: Access and
affordability today versus incentives
for innovation tomorrow?
• Directions from Public Policy and
Management Practitioners
• Pivotal role of evidence-based
policy (not policy-based evidence)

3. AGENDA FOR THE TALK
• Summary of past work
• On-going work
• Open questions

4. SUMMARY OF PAST RESEARCH
• Access versus Innovation Incentives (evidence from
US Pharmaceutical Markets)
• Welfare effects of differential pricing of medicines
in India
• Ring-leaders & cartels in Indian medicine markets
• Physicians and their role in diffusion of irrational
medicines in India
• Spatial peer effects in diffusion of UHC in India (the
Karnataka VAS experiment)
• Does competition respond to firm entry with
stakeholder orientation in healthcare markets?

5. ACCESS VERSUS INNOVATION

6. ACCESS VERSUS INNOVATION

7. DIFFERENTIAL PRICING AND WELFARE EFFECTS

8. DIFFERENTIAL PRICING AND WELFARE EFFECTS

9. CARTEL POLICING USING TARGETED PUNISHMENT STRATEGIES

10. CARTEL POLICING USING TARGETED PUNISHMENT STRATEGIES

11. PHYSICIANS & IRRATIONAL MEDICINES IN INDIA
Source: https://www.statnews.com/2016/03/17/stat-harvard-opioid-poll/

12. PHYSICIANS & IRRATIONAL MEDICINES IN INDIA

13. PHYSICIANS & IRRATIONAL MEDICINES IN INDIA

14. DIFFUSION OF UHC COURTESY SPATIAL PEER EFFECTS

15. DOES COMPETITION RESPOND TO FIRM ENTRY WITH
STAKEHOLDER ORIENTATION

16. TO SUMMARIZE PAST WORK
• Interdisciplinary (economics, strategic management,
business ethics and firm behaviour, global health
and public policy) and Collaborative
• Unit of observation (individuals, physicians, firms,
markets, organizations, households, villages)
• Evidence based policy, not policy based evidence
(Go where evidence takes us as scientists,
can/should we go beyond?)

17. SOME ON-GOING PROJECTS
• Pandemics and vaccine market response with new
products (India and the H1N1 shock).
• Experiments on disempowerment and risks women
differentially take to buy fairness creams?
• Price controls and differential fixed costs of entry &
welfare effects in Indian malarial markets.
• IPR shifts in India, changing firm organizational structure
and within-market churns.
• ODA & Risky Bio-Pharmaceutical VC funding in EU
Healthcare Entrepreneurial Activity.

18. OPEN QUESTIONS – HONESTLY SEVERAL

19. THANKS TO THE ICICI BANK CHAIR
Official: https://www.iima.ac.in/web/faculty/faculty-profiles/chirantan-chatterjee
Personal: https://sites.google.com/view/chirantanonline/
SSRN: http://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfm?per_id=830407
Scholar Google: http://scholar.google.co.in/citations?user=8NcyqgYAAAAJ&hl=en&oi=ao
Twitter: https://twitter.com/chiruchat
Linkedin: https://in.linkedin.com/in/chirantanchatterjee